Lpath, Inc. (NASDAQ:LPTN) is to present the Nexus Phase 2 study data of iSONEP™ at the American Academy of Ophthalmology (AA0) Annual Meeting Retina Subspecialty Day in Las Vegas on November 14, 2015. A Nexus investigator, Thomas, Ciulla, M.D., who is also a practicing retinal surgeon and ophthalmologist in Indianapolis, IN., will make the oral presentation.
Lpath, the leader in bioactive lipid-targeted therapeutics earlier in May, had announced that the iSONEP failed to meet both the primary and secondary key endpoints in Phase 2 clinical, randomized trial. The prospective Nexus trial was conducted in the U.S. on 158 patients afflicted with wet age-related macular degeneration (wet AMD). These enrolled patients had shown sub-response to the existing anti-vascular endothelial growth factor (VEGF) therapies.
Nexus Trial Do Not Show Significant Improvement
When the patients were tried in the Nexus trial, they failed to show any significant statistical improvement in their visual acuity. The treatment that was carried out for 120 days included iSONEP as a monotherapy or adjunctive. The company further analyzed the available data, including the additional anatomical endpoints for understanding each segment of the trial in a better way.
These findings are to be revealed at the AAO Annual Meeting presentation. The presentation slides are also available on the official website of the company –www.Ipath.com.
Drug Discovery Engine- ImmuneY2™
ImmuneY2™ from Lpath is an existing drug-discovery engine known for its exceptional ability to inhibit the disease-causing bioactive lipids, bind, and generate therapeutic antibodies. Apart from that, the company also has come up with four drug candidates and has already tried them for the first two mid-stage trials. These drugs are being developed to target the bioactive lipids that cause a plethora of diseases.
Atkinson Appointed as New CEO
In a surprising move, the company appointed Mr. Gary Atkinson, the current chief financial officer as the interim chief executive officer of Lpath. Atkinson will now be serving dual responsibilities at the company office and is expected to improve the overall profile of Lpath in the market.